Lyell Immunopharma (LYEL) Revenue (2020 - 2026)

Lyell Immunopharma has disclosed Revenue across 7 years of filings, most recently posting $2000.0 for Q1 2026.

• Revenue for Q1 2026 came in at $2000.0, down 71.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $31000.0 (down 52.31% YoY), and the FY2025 annual result was $36000.0, down 40.98% from the prior year.
• Revenue came in at $2000.0 for Q1 2026 at Lyell Immunopharma, down from $6000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $48.4 million in Q4 2022 to a low of $2000.0 in Q1 2026.
• The 5-year median for Revenue is $13000.0 (2023), against an average of $5.0 million.
• Across the five-year window, Revenue jumped 1614.6% in 2022 and tumbled 99.97% in 2023, its largest moves.
• Lyell Immunopharma's Revenue stood at $48.4 million in 2022, then sank by 99.97% to $13000.0 in 2023, then fell by 15.38% to $11000.0 in 2024, then sank by 45.45% to $6000.0 in 2025, then slumped by 66.67% to $2000.0 in 2026.
• The last three Revenue figures came in at $2000.0 (Q1 2026), $6000.0 (Q4 2025), and $15000.0 (Q3 2025), per Business Quant data.